December 8, 2025BloodOpen Access

Targeting hemolysis and raas: Osivelotor and losartan ameliorate sickle cell renal pathology

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Preclinical model shows nephron function improved with Osivelotor and losartan in sickle cell disease, suggesting renoprotective strategies.

Osivelotor treatment improved kidney function and reduced hemolytic biomarkers in sickle cell disease mice.
Sickle cell disease mice treated with Osivelotor showed significantly better renal function and lower oxidative stress.
Observational analysis of transgenic sickle mice evaluated kidney injury and function after treatment with Osivelotor and losartan.
Combined therapy indicates potential for addressing kidney damage in sickle cell disease beyond individual treatments.

Setty et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Preclinical model shows nephron function improved with Osivelotor and losartan in sickle cell disease, suggesting renoprotective strategies.